Inovio, with path to market opening up, drafts accelerated approval talking points ahead of FDA meeting

Inovio Pharmaceuticals has a line of sight on an accelerated approval. Weeks after getting the green light to use data from a completed single-arm phase 1/2 clinical trial to support a filing, the DNA medicine specialist has set out what the opening up of the regulatory pathway means for its rare disease drug.